Clinical Trials Logo

Clinical Trial Summary

The prevalence of type 2 diabetes mellitus (T2DM) in Qatar and nations worldwide has increased in recent decades into epidemic proportions. Cardiovascular (CVD) disease is the leading cause of death in T2DM patients. Approximately 80% of T2DM patients will die because of CV cause. Congestive heart failure (CHF) is a major cause of CV death in T2DM, and it also is responsible for significant morbidity and health care expenditure due to high rate of hospitalization for heart failure.


Clinical Trial Description

Community based studies have demonstrated similar prevalence of HF with reduced ejection fraction (HFpEF) and HF with reduced LV function (HFrEF) in patients hospitalized for CHF. Moreover, the prevalence of HFrEF is declining over the past two decades, whereas that of HFpEF is progressively increasing. Progressive increase in obesity and T2DM prevalence is likely among the principal factors responsible for the steady increase in HFpEF prevalence.

The aims of the present study are to examine whether therapies that correct the myocardial metabolic abnormalities present in subjects with T2DM and diastolic dysfunction improve myocardial diastolic dysfunction and reduce the rate of hospitalizations in patients with HFpEF

The primary objective of the study is to examine the effect of combination therapy with pioglitazone (15 mg) plus dapagliflozin (10 mg) versus placebo on hospitalization for heart failure in patients with HFpEF.

Eligible subjects, who consent for participating in the study, will be seen by the study coordinator. Medical history and physical examination will be performed. Each subject will receive the following measurements:

Medical history and physical examination including weight, height, waist, blood pressure and pulse.

Blood tests:

Screening: CBC, Blood chemistry, fasting plasma glucose concentration, HbA1c, renal and liver function, lipid profile, TSH, serum iron, iron biding capacity and ferritin.

Plasma metabolites: ketone, lactate, bicarbonate, venous PH and plasma free fatty acid.

Hormones: insulin, C-peptide, glucagon, NT proBNP, angiotensin II, plasma renin activity, and aldosterone.

Inflammatory markers: adiponectin, hsCRP, IL-2, IL-6 and IL-12, F2-isoprostane, oxidized LDL.

Vascular Measurements: Measurement of pulse wave velocity, and central aortic pulse pressure, with sphygmocor.

Measurement of total body fat mass with Bioimpedence. Echocardiography

Patients will be consented on the day of discharge or during the outpatient visit in the Cardiology Clinic. Consented patients will be referred to the CRC within one week to perform the echocardiography and vascular measurements. Patients will be asked to come to CRC after overnight fast and blood samples will be drawn for the above mentioned blood tests, after which echocardiography and vascular measurements will be performed.

Randomization and Intervention:

After completing the baseline studies, patients will be randomized into two groups to receive in a double blind fashion:

Group 1: combination of pioglitazone plus dapagliflozin, or Group 2: Placebo (Beta blockers, ACEI, ARB, and aldosterone )

Patients in both groups will be matched for age, gender, BMI, HbA1c, systolic BP and LVEF. Randomization will be made by the pharmacist at the Heart Hospital and the randomization code will be maintained at the hospital pharmacy. Patients will be randomized in blocks of 4 while the group means are matched for the above parameters ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03794518
Study type Interventional
Source Hamad Medical Corporation
Contact Nidal Asaad, MD
Phone 44395578
Email nasaad@hamad.qa
Status Not yet recruiting
Phase Phase 3
Start date March 2019
Completion date December 2021

See also
  Status Clinical Trial Phase
Completed NCT05009251 - Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake N/A
Completed NCT05509270 - Efficacy of Communication Modalities for Promoting Flu Shots N/A
Completed NCT05343208 - Effectiveness of Online Therapy to Prevent Burnout N/A
Completed NCT03833713 - Utilizing Text Messaging to Improve Vehicle Safety Among At-Risk Young Adults N/A
Recruiting NCT06001892 - Tennessee Youth Prepared for Success N/A
Completed NCT04323137 - Encouraging Flu Vaccination Among High-Risk Patients Identified by ML N/A
Recruiting NCT03109899 - Personalized HIV and STI Testing Tool N/A
Recruiting NCT05017948 - Alleviating Geriatric Inpatients' Medication-related Iatrogenesis N/A
Completed NCT05509283 - Nudging Flu Vaccination in Patients at Moderately High Risk for Flu and Flu-related Complications N/A
Recruiting NCT05353283 - PrEP Point-of-Care Brief-Intervention for Adherence Among Young Men Who Have Sex With Men N/A
Recruiting NCT04294381 - Achievement and Adherence to Behavioral Health Goals in the Setting of Patient-Directed Goal Choice N/A
Recruiting NCT04500977 - Training Health Promotion Women Community Leaders N/A
Recruiting NCT03319927 - Reducing Pesticide Exposures in Child Care Centers N/A
Completed NCT03981952 - Salmonella Conjugates CVD 1000: Study of Responses to Vaccination With Trivalent Invasive Salmonella Disease Vaccine Phase 1
Completed NCT03177512 - LYNX: A Novel Mobile App to Support Linkage to HIV/STI Testing PrEP for Young Men Who Have Sex With Men N/A
Recruiting NCT04374747 - Fruit and Vegetable Intervention in Lactating Women to Reduce Breast Cancer Risk N/A
Recruiting NCT06020469 - Comparative Effects of Ciprofol and Propofol on Pain Intensity on the First Day After Surgery: a Retrospective, Propensity Score Matched, Cohort Study
Recruiting NCT05569460 - Construction of Perioperative Medical Data Platform and Its Typical Practice to Predict Postoperative Acute Moderate to Severe Pain With Machine Learning Models
Not yet recruiting NCT03222960 - Improving Caries Risk Using Propolis-containing Versus Fluoride-containing Toothpastes in High Caries Risk Patients N/A
Completed NCT03965221 - Comparison of Men's Prevention Apps to Research Efficacy N/A